Study Title | BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network) |
---|---|
Protocol ID | NL59901.078.17 (BlinFant) |
Disease (Sub Disease) | Acute Lymphoblastic Leukaemia (ALL) |
Diagnosis Stage | New diagnosis |
Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ Princess Maxima Center for Pediatric Oncology & Utrecht |
Links | https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379482&isReview=true |
Trial Status | Closed to Recruitment |
Trial Open Date | 20/07/2018 |
Study Type | Treatment |
Phase | Pilot |
Age Eligibility | <12 months |
ANZCTR | ACTRN12620000542998 |